Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen
- Development stage
- Approved
- Lead developer
- GSK
- Modality
- Vaccines & Immunotherapeutics
- Administration
- Intramuscular
01
Overview
Neisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate antigen is a biologic vaccine component used for active immunization against invasive meningococcal disease. It consists of the purified capsular polysaccharide of *N. meningitidis* serogroup W-135 covalently bound to a tetanus toxoid carrier protein. This conjugation process converts the T-cell independent polysaccharide into a T-cell dependent antigen, which enhances immunogenicity by recruiting T-cell help, leading to higher antibody titers and the induction of immunological memory. It is one of the four active conjugate antigens contained in the quadrivalent vaccine MenQuadfi, developed by Sanofi, which is indicated for use in individuals aged 6 weeks and older to prevent disease caused by serogroups A, C, W, and Y.
- Brand names
- MenQuadfi
- Other names
- MenW-TTMeningococcal group W-135 conjugate vaccineNeisseria meningitidis group W-135 capsular polysaccharide tetanus toxoid conjugate
02
Targets
MenW CPS (Neisseria meningitidis serogroup W capsular polysaccharide)
Beyond the preview
Go deeper on neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on neisseria meningitidis group w-135 capsular polysaccharide tetanus toxoid conjugate antigen.